Deploy AI agents that manage adverse event reporting, clinical trial notifications, and physician outreach — with gated approval ensuring regulatory compliance at every step.
Pharmaceutical companies operate under some of the most stringent regulatory frameworks in any industry. Every email communication about drugs, clinical trials, adverse events, or promotional materials carries significant legal weight and is subject to FDA scrutiny. A promotional email that lacks fair balance information, or an adverse event report that misses its reporting window, can result in warning letters, consent decrees, or criminal prosecution.
The volume and complexity of pharmaceutical email is driven by multiple stakeholders — clinical research organizations running trials across dozens of sites, medical affairs teams communicating with healthcare providers, pharmacovigilance teams tracking adverse events globally, and commercial teams managing promotional campaigns that must comply with FDA regulations on drug advertising. Each communication stream has distinct compliance requirements that demand different levels of oversight.
AI agents can transform pharmaceutical email operations by automating routine communications like site status updates, enrollment notifications, and sample tracking confirmations. However, the regulatory environment demands that promotional content, adverse event communications, and clinical data transmissions undergo rigorous human review before delivery to ensure compliance with 21 CFR Part 11, GxP guidelines, and FDA promotional rules.
Serious adverse events must be reported to the FDA within 15 calendar days, and fatal or life-threatening events within 7 days. Email communications about adverse events must be accurate, timely, and properly documented with full audit trails per 21 CFR Part 11.
All promotional emails to healthcare professionals must include fair balance information — presenting risks alongside benefits. FDA Division of Drug Marketing monitors promotional communications and issues warning letters for non-compliant materials.
Emails related to clinical trials must follow ICH-GCP guidelines and maintain clear separation between promotional and scientific communications. Site communications must be documented as part of the trial master file.
FDA requires that electronic records and signatures used in drug development meet strict requirements for audit trails, access controls, and system validation. Email systems used for regulated communications must demonstrate compliance.
Global pharmaceutical companies must comply with FDA, EMA, and country-specific regulatory bodies simultaneously. Email communications about the same drug may require different content and disclosures depending on the recipient's jurisdiction.
Every AI-composed email related to adverse events, clinical trials, or promotional content undergoes mandatory medical/legal/regulatory (MLR) review before delivery. This prevents non-compliant communications from reaching healthcare providers or regulatory agencies.
AI agents monitor incoming emails for potential adverse event reports, tag them with urgency levels, and alert pharmacovigilance teams. Outbound adverse event communications are routed through gated approval with timestamp documentation for regulatory submissions.
AI agents draft physician outreach emails using approved messaging frameworks. Gated send ensures medical affairs or MLR teams review each message for fair balance, off-label content, and proper ISI inclusion before delivery to healthcare professionals.
Automate routine trial site communications like enrollment updates, query responses, and visit reminders. Gated send oversight ensures site-facing communications maintain GCP compliance and proper documentation for the trial master file.
AI agents manage PDMA-compliant sample tracking communications between field representatives and sample management teams. Monitored mode provides oversight for routine confirmations while maintaining audit trails.
const response = await fetch('https://api.multimail.dev/v1/mailboxes', {
method: 'POST',
headers: {
'Authorization': 'Bearer mm_live_your_api_key',
'Content-Type': 'application/json'
},
body: JSON.stringify({
address: '[email protected]',
display_name: 'Drug Safety & Pharmacovigilance',
oversight_mode: 'gated_all',
forward_to: '[email protected]'
})
});
const mailbox = await response.json();
console.log(`Pharmacovigilance mailbox created: ${mailbox.id}`);Set up a dedicated mailbox for adverse event communications with gated_all oversight to ensure every outbound message is reviewed by pharmacovigilance staff.
"cm">// MCP tool calls for adverse event triage
const inbox = await mcp.check_inbox({
mailbox: '[email protected]',
unread: true
});
for (const message of inbox.messages) {
const email = await mcp.read_email({ message_id: message.id });
const tags = ['ae-triage'];
"cm">// Classify severity
if (email.body.match(/death|fatal|life.threatening/i)) {
tags.push('ae-serious', 'ae-7day-report', 'priority-critical');
} else if (email.body.match(/hospitalization|disability|congenital/i)) {
tags.push('ae-serious', 'ae-15day-report', 'priority-high');
} else if (email.body.match(/adverse|side effect|reaction/i)) {
tags.push('ae-nonserious', 'priority-standard');
}
"cm">// Tag product if identifiable
if (email.body.match(/DrugNameA/i)) tags.push('product-drug-a');
if (email.body.match(/DrugNameB/i)) tags.push('product-drug-b');
await mcp.tag_email({ message_id: message.id, tags });
}Use the MCP server to have an AI agent read incoming emails for potential adverse event signals and tag them by severity for pharmacovigilance review.
const response = await fetch('https://api.multimail.dev/v1/emails', {
method: 'POST',
headers: {
'Authorization': 'Bearer mm_live_your_api_key',
'Content-Type': 'application/json'
},
body: JSON.stringify({
from: '[email protected]',
to: '[email protected]',
subject: 'Clinical Data Update - DrugName Phase III Results',
text: 'Dear Dr. Smith, we are writing to share recently published Phase III trial results for DrugName in the treatment of [indication]. The study demonstrated [efficacy data]. Important Safety Information: [complete ISI including contraindications, warnings, precautions, and adverse reactions]. Please see full Prescribing Information at [link]. For medical inquiries, contact our Medical Information team at 1-800-555-0100.',
tags: ['hcp-outreach', 'mlr-review-required', 'product-drugname']
})
});
const email = await response.json();
console.log(`Status: ${email.status}`); "cm">// 'pending_approval'Compose a healthcare provider outreach email that enters the MLR review queue before delivery, ensuring promotional compliance.
"cm">// Send enrollment updates to trial sites
const trialSites = await getActiveSites('TRIAL-2024-001');
for (const site of trialSites) {
await mcp.send_email({
from: '[email protected]',
to: site.coordinator_email,
subject: `Enrollment Update - Study TRIAL-2024-001 - Site ${site.number}`,
text: `Dear ${site.coordinator_name}, this is your weekly enrollment update for Study TRIAL-2024-001. Site ${site.number} enrollment: ${site.enrolled}/${site.target} subjects. Overall study enrollment: ${totalEnrolled}/${totalTarget}. Next monitoring visit scheduled: ${site.next_visit}. Please ensure all source documents are updated prior to the visit. Contact your CRA with questions.`
});
await mcp.add_contact({
email: site.coordinator_email,
name: site.coordinator_name,
tags: ['trial-site', `site-${site.number}`, 'TRIAL-2024-001']
});
}Automate enrollment status updates to clinical trial sites with gated send oversight for GCP compliance.
| Regulation | Requirement | How MultiMail helps |
|---|---|---|
| FDA 21 CFR Part 11 (Electronic Records) | Electronic records used in drug development must maintain complete audit trails showing who created, modified, or transmitted records, with timestamps and electronic signatures. Systems must be validated and access must be controlled. | MultiMail provides immutable audit logs for every email action with timestamps, actor identity, and content metadata. API-key-based access controls restrict mailbox access to authorized personnel, and the gated approval workflow creates a documented review chain. |
| FDA Promotional Guidelines (OPDP/APLB) | Promotional communications to healthcare professionals must include fair balance of risk and benefit information, must not be false or misleading, and must include Important Safety Information. The Office of Prescription Drug Promotion monitors compliance. | Gated_send oversight routes all HCP-facing emails through MLR review queues before delivery. AI agents can flag emails missing ISI or fair balance content, and the approval workflow documents that each promotional email was reviewed per internal SOPs. |
| ICH-GCP Guidelines (E6(R2)) | Clinical trial communications must follow Good Clinical Practice guidelines, maintaining clear documentation of all trial-related communications as part of the trial master file. Sponsor-site communications must be traceable and verifiable. | Every clinical trial email is logged with full audit trails suitable for TMF documentation. Gated send ensures trial communications are reviewed by clinical operations before delivery, and tagging enables easy retrieval of all communications related to a specific study. |
| PDMA (Prescription Drug Marketing Act) | Drug sample distribution must be tracked and documented, including all communications related to sample requests, deliveries, and reconciliations. Sample tracking records must be maintained and available for FDA inspection. | Dedicated mailboxes for sample management with monitored oversight provide complete audit trails of all sample-related communications. Tagging by representative, product, and transaction type enables rapid retrieval during FDA inspections. |
Email infrastructure built for AI agents. Verifiable identity, graduated oversight, and a 38-tool MCP server. Formally verified in Lean 4.